Clonotypic B cells are frequently isolated from the peripheral blood of patients with multiple myeloma (MM).[1][1] These clonotypic B cells may be the clonogenic cells of MM. We have hypothesized that rituximab, a chimeric CD20 monoclonal antibody, may be a useful maintenance therapy in MM after
No takes yet. Share an insight, caveat, or question.
Lim et al. (2004) studied this question.